# What We Know About the Cicada Variant and Why It’s Being Watched The pandemic phase has shifted, but the virus has not disappeared. SARS-CoV-2 continues to evolve, and currently, health authorities are focusing attention on a specific Omicron subvariant known as BA.3.2. In scientific monitoring circles, it has acquired the nickname Cicada. While the name might suggest a sudden emergence, this variant has been circulating since 2024, largely under the radar until recent genomic surveillance brought it into focus. For patients and families, the immediate takeaway is one of watchful monitoring rather than alarm: current data suggests similar symptoms to previous waves without evidence of increased severity. ## The Science Behind the Spike The primary reason epidemiologists are tracking BA.3.2 closely lies in its genetic structure. The variant carries an unusually high number of mutations—approximately 70 to 75 changes specifically within the spike protein. This is the part of the virus that binds to human cells, and it is also the primary target for vaccine-induced immunity. Such a high density of mutations raises theoretical concerns about immune evasion. Experts note that these changes could make it easier for the virus to partially bypass immunity gained from prior infection or vaccination. However, immune evasion does not automatically equate to greater danger. The World Health Organization (WHO) currently classifies BA.3.2 as a Variant Under Observation. This designation means it warrants study, but it has not met the threshold for a Variant of Concern based on current clinical outcomes. ## Symptoms and Clinical Severity For the average person, the experience of infection with Cicada appears consistent with recent Omicron lineages. Reported symptoms include fever, fatigue, cough, runny nose, and body aches. Some clinical reports have noted sore throats described as severe, sometimes compared to earlier variants, though robust data confirming a distinct change in symptom profile remains limited. Crucially, severity metrics remain stable. The WHO stated in December that there is no data indicating increased hospitalizations or deaths associated with this variant compared to others currently circulating. Infectious disease specialists, including those monitoring data in the U.S. And Europe, align with this assessment. The virus is changing its shape to spread, but it is not necessarily changing its capacity to cause severe disease in vaccinated or previously exposed populations. ## Global Spread and Local Presence BA.3.2 was first detected in South Africa in 2024. By early 2025, it had been identified in over 20 countries. Surveillance data indicates stronger establishment in Northern Europe, where variants like this sometimes gain a foothold before spreading elsewhere. In countries such as Denmark and the Netherlands, the variant accounted for a significant portion of sequenced cases during recent monitoring periods. In Switzerland, the variant appeared in late 2025. Wastewater monitoring suggests that while Cicada is present, it is not currently dominating the infection landscape. It is co-circulating with other known lineages, including variants previously nicknamed Frankenstein, Nimbus, and KP.3. This pattern of co-circulation is typical for the current phase of the pandemic, where multiple subvariants compete rather than one completely replacing others.
Vaccination Guidance and Risk Groups
Updated vaccines remain a critical tool for preventing severe outcomes. Health authorities recommend updated boosters (such as LP8.1 formulations from major manufacturers) for specific high-risk groups, particularly during the autumn and winter seasons.
Priority groups typically include:
- Adults aged 65 and older
- Individuals aged 16+ with underlying health conditions
- Individuals with Trisomy 21
- Pregnant persons
Timing for booster doses is often recommended between October and December to ensure coverage during peak respiratory virus season. Consult your primary care provider for eligibility based on your specific health history.
## Layered Protection Strategies While the variant presents challenges for immune recognition, standard public health measures remain effective. Physical distancing from those who are actively ill and wearing masks in crowded indoor settings continue to reduce transmission risk. For those eligible, updated vaccines provide reliable protection against severe disease, even if their ability to prevent mild infection is reduced by the variant’s mutations. The presence of BA.3.2 underscores the importance of sustained surveillance rather than reactive panic. Health systems are tracking wastewater data and genomic sequences to detect shifts in real-time. For now, the virus is behaving within expected parameters for an Omicron descendant. As we navigate this continued evolution of the virus, how do you decide when to update your own protection measures during respiratory virus season?
